Szatmári Viktor, Ji Yuan, Herwijnen Bianca van, Feng Mei, Wang Michael Zhou, Bossu Alexandre, van der Heyden Marcel A G
Department of Clinical Sciences of Companion Animals, Utrecht University, Utrecht, The Netherlands.
Department of Medical Physiology, University Medical Center Utrecht, Utrecht, The Netherlands.
J Vet Intern Med. 2018 Sep;32(5):1549-1554. doi: 10.1111/jvim.15242. Epub 2018 Aug 5.
The inward rectifier inhibitor pentamidine analogue 6 (PA-6) is effective in cardioversion of goats with persistent rapid pacing induced atrial fibrillation (AF) and is not proarrhythmic in dogs with experimental chronic 3rd-degree AV block. Efficacy and safety in the clinical setting are unknown.
That PA-6 would be effective in converting AF to sinus rhythm (SR) in dogs with naturally occurring AF, without the presence of overt adverse effects.
Ten client-owned large and giant breed dogs.
Animals with persistent or permanent AF were recruited for our prospective study. PA-6 was administered IV as a bolus of 2.5 mg/kg 10 min followed by a maintenance infusion of 0.04 mg/kg min for a maximum of 50 minutes in conscious dogs. Standard 6 lead limb ECG was recorded during the infusion. Visible and audible signs of adverse effects were scored during the entire procedure.
PA-6 did not induce changes in QRS duration (54.7 ± 4.6 versus 56.7 ± 6.1 ms, P = .42), QTc interval (241.1 ± 19.5 versus 258.7 ± 19.8 ms, P = .061) or RR interval (363.4 ± 84.6 versus 440.8 ± 96.3 ms, P = .072) at the end of the bolus. No cardioversion to SR was observed in any dog. Three dogs displayed no adverse effects. Five dogs had premature ventricular depolarizations during PA-6 infusion on the ECG. Respiratory distress with laryngeal stridor, subtle muscle twitching, and mild generalized muscular weakness were noncardiac adverse effects observed in 5 dogs. Adverse effects resolved spontaneously.
Chronic naturally occurring AF in large and giant breed dogs could not be cardioverted to SR by PA-6.
内向整流抑制剂喷他脒类似物6（PA - 6）对持续性快速起搏诱发心房颤动（AF）的山羊具有有效的转复作用，且对实验性慢性三度房室传导阻滞的犬无促心律失常作用。其在临床环境中的疗效和安全性尚不清楚。
PA - 6能有效将自然发生AF的犬的AF转为窦性心律（SR），且无明显不良反应。
10只客户拥有的大型和巨型犬种。
招募持续性或永久性AF的动物进行前瞻性研究。在清醒犬中，PA - 6以2.5 mg/kg的剂量静脉推注10分钟，随后以0.04 mg/kg·min的速度维持输注，最长50分钟。输注期间记录标准6导联肢体心电图。在整个过程中对可见和可闻的不良反应体征进行评分。
推注结束时，PA - 6未引起QRS时限（54.7±4.6对56.7±6.1毫秒，P = 0.42）、QTc间期（241.1±19.5对258.7±19.8毫秒，P = 0.061）或RR间期（363.4±84.6对440.8±96.3毫秒，P = 0.072）的变化。未观察到任何一只犬转为SR。3只犬未出现不良反应。5只犬在PA - 6输注期间心电图出现室性早搏。5只犬出现呼吸窘迫伴喉喘鸣、轻微肌肉抽搐和轻度全身性肌无力等非心脏不良反应。不良反应自行缓解。
PA - 6不能将大型和巨型犬种的慢性自然发生AF转为SR。
